Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells.

Leukemia research ·Vol. 33 ·No. 9 ·2009-09-00 ·Pages 1255-9

Boissel L, Betancur M, Wels WS, Tuncer H, Klingemann H

Abstract

An emerging treatment option for chronic lymphocytic leukemia (CLL) is to make cytotoxic immune cells express a chimeric antigen receptor (CAR) that recognizes specific surface molecules on CLL cells. Here an mRNA coding for an anti-CD19 CAR was transfected into the NK-92 cell line by electroporation. In contrast to cDNA, mRNA resulted in high transfection efficiency (47.2 +/- 8% versus <5% for cDNA) with minimal effect on cell viability. NK-92 cells expressing anti-CD19 CAR killed previously resistant CD19+ B-ALL cell lines, as well as primary CLL cells and therefore may present a safe, cell-based, targeted treatment for patients with CLL.

MeSH Terms

Antigens, CD19/genetics Base Sequence Cell Line, Tumor DNA Primers Electroporation Humans Killer Cells, Natural/immunology Leukemia, Lymphocytic, Chronic, B-Cell/immunology RNA, Messenger/genetics Recombinant Fusion Proteins/genetics Transfection

Chemicals

Antigens, CD19 DNA Primers RNA, Messenger Recombinant Fusion Proteins

Authors & Affiliations

5 authors, click to expand affiliations / ORCID

Boissel Laurent

Molecular Oncology Research Institute-Tufts Medical Center, 800 Washington Street-Box 5609, Boston, MA 02111, USA. lboissel@tuftsmedicalcenter.org

Betancur Monica

Wels Winfried S

Tuncer Hande

Klingemann Hans

References (24)

24 references, click to expand

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
N Engl J Med. 2000 Dec 14;343(24):1750-7 PMID: 11114313
Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92.
J Hematother Stem Cell Res. 2001 Aug;10(4):535-44 PMID: 11522236
Adoptive cellular immunotherapy for viral diseases.
Bone Marrow Transplant. 2008 Jan;41(2):193-8 PMID: 17982497
Differential killing of pre-B acute lymphoblastic leukaemia cells by activated NK cells and the NK-92 ci cell line.
Clin Exp Immunol. 2002 Aug;129(2):265-71 PMID: 12165082
Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells.
Leukemia. 1994 Apr;8(4):652-8 PMID: 8152260
Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction.
Blood. 2002 Aug 15;100(4):1265-73 PMID: 12149207
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.
Blood. 2005 Apr 15;105(8):3051-7 PMID: 15632206
NK cell receptors and their ligands in leukemia.
Leukemia. 2008 Feb;22(2):249-57 PMID: 18046448
Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia.
Ann Intern Med. 2006 Sep 19;145(6):435-47 PMID: 16983131
Up on the tightrope: natural killer cell activation and inhibition.
Nat Immunol. 2008 May;9(5):495-502 PMID: 18425106
Chronic lymphocytic leukemia: a changing natural history?
Leukemia. 1997 Jun;11(6):775-8 PMID: 9177426
Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells.
Cancer Immunol Immunother. 2008 Mar;57(3):411-23 PMID: 17717662
NK cell-mediated immune response against cancer.
Surg Oncol. 2007 Dec;16 Suppl 1:S3-5 PMID: 18032029
A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood.
Biol Blood Marrow Transplant. 1996 May;2(2):68-75 PMID: 9118301
Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.
Biol Blood Marrow Transplant. 2008 Sep;14(9):1031-1038 PMID: 18721766
Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.
Cytotherapy. 2008;10(6):625-32 PMID: 18836917
Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
Cytotherapy. 2006;8(2):105-17 PMID: 16698684
Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect.
Blood. 2002 Sep 15;100(6):1935-47 PMID: 12200350
Synthetic messenger RNA as a tool for gene therapy.
Hum Gene Ther. 2006 Oct;17(10):1027-35 PMID: 17007566
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.
Blood. 2005 Jan 1;105(1):49-53 PMID: 15138165
The T-body approach: redirecting T cells with antibody specificity.
Handb Exp Pharmacol. 2008;(181):329-42 PMID: 18071952
Establishment and characterization of a human leukemic cell line (SR-91) with features suggestive of early hematopoietic progenitor cell origin.
Leuk Lymphoma. 1994 Feb;12(5-6):463-70 PMID: 8180609
Functions of natural killer cells.
Nat Immunol. 2008 May;9(5):503-10 PMID: 18425107
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.
J Clin Oncol. 2007 Dec 10;25(35):5616-23 PMID: 17984186

Article Info

Journal

Leukemia research

Abbr.

Leuk Res

ISSN

1873-5835

DOI

10.1016/j.leukres.2008.11.024

lboissel@tuftsmedicalcenter.org

Published

2009-09-00

Epub

2009-00-14

Pages

1255-9

Language

English

Region

England

NLM ID

7706787

PMCID

PMC3047414

Subset

Grants

NCI NIH HHS · R01 CA090576 · United States

NHLBI NIH HHS · R01 HL093981 · United States

NHLBI NIH HHS · R01 HL093981-01A1 · United States

External Links

PubMed source DOI: 10.1016/j.leukres.2008.11.024 PMC Full Text View journal details

Analysis Services

Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells.

Contact

WeChat Official Account